Viewing Study NCT05983133


Ignite Creation Date: 2025-12-25 @ 2:48 AM
Ignite Modification Date: 2025-12-26 @ 1:30 AM
Study NCT ID: NCT05983133
Status: RECRUITING
Last Update Posted: 2025-12-08
First Post: 2023-08-01
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Organization:

Study Overview

Official Title: A Phase 1 Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Status: RECRUITING
Status Verified Date: 2025-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.

Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic).

This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants. Part C will use the dose found in parts A and B to find out how safe PF-08046052/SGN-EGFRd2 is and if it works to treat solid tumor cancers.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
C5841001 OTHER Alias Study Number View